Ginkgo Bioworks (DNA) Q4 Revenue Tops Consensus

Ginkgo Bioworks (NYSE: DNA) reported Q4 EPS of ($1.10), $1.06 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $148.5 million versus the consensus estimate of $94.81 million.

GUIDANCE:

Ginkgo Bioworks sees FY2022 revenue of $325-340 million, versus the consensus of $305.8 million.

• Ginkgo expects to add 60 new Cell Programs to the Foundry platform in 2022.
• Ginkgo expects Total revenue of $325 to $340 million in 2022.
• Ginkgo expects Foundry revenue of $165 to $180 million in 2022.
• While Biosecurity remains an uncertain business, Ginkgo is committed to investing in the space and expects Biosecurity revenue in 2022 of at least $160 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• NVE Corporation names new CEO and expands board to seven members